Tivic Health Systems, Inc. (TIVC)
NASDAQ: TIVC · Real-Time Price · USD
4.130
-0.070 (-1.67%)
At close: May 30, 2025, 4:00 PM
4.010
-0.120 (-2.90%)
After-hours: May 30, 2025, 5:11 PM EDT
Tivic Health Systems Revenue
Tivic Health Systems had revenue of $70.00K in the quarter ending March 31, 2025, a decrease of -79.04%. This brings the company's revenue in the last twelve months to $516.00K, down -54.50% year-over-year. In the year 2024, Tivic Health Systems had annual revenue of $780.00K, down -33.67%.
Revenue (ttm)
$516.00K
Revenue Growth
-54.50%
P/S Ratio
3.32
Revenue / Employee
$73,714
Employees
7
Market Cap
3.63M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
TIVC News
- 15 days ago - Tivic Health Systems Inc. (TIVC) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Tivic Reports First Quarter 2025 Financial Results and Provides Updates on Business Transformation - Business Wire
- 17 days ago - Tivic Health Enters GMP Manufacturing Validation Agreement with Scorpius BioManufacturing in Preparation for FDA Submission - Business Wire
- 18 days ago - Tivic Expands VNS Intellectual Property Portfolio - Business Wire
- 22 days ago - Tivic Health to Report First Quarter 2025 Financial Results on May 15th Via Conference Call and Webcast - Business Wire
- 5 weeks ago - Tivic Health Reports White House Briefing and FDA Meetings Secured Positive Interest in Potential Military and Defense Applications of Its Product Candidates - Business Wire
- 6 weeks ago - Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia - Business Wire
- 7 weeks ago - Tivic Health Systems, Inc. Regains Compliance with NASDAQ Minimum Bid Price Listing Rule - Business Wire